A bifunctional colchicinoid that binds to the androgen receptor

Molecular Cancer Therapeutics

Volumn 6, Issue 8, 2007, Pages 2328-2336

  Sharifi, Nima ^a,b   Hame, Ernest ^a   Lill, Markus A ^c   Risbood, Prabhakar ^b   Kane Jr , Charles T ^d   Hossain, Md Tafazzal ^d   Jones, Amanda ^e   Dalton, James T ^e   Farrar, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c PURDUE UNIVERSITY   (United States)

^d Starks Associates Inc   (United States)

^e OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; COLCHICINE; COLCHICINE CYANONILUTAMIDE CONJUGATE; COLCHICINOID; NILUTAMIDE; THIOCOLCHICINE; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOPLASM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LIGAND BINDING; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; SIMULATION;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; COLCHICINE; CYTOPLASM; HUMANS; IMIDAZOLIDINES; MALE; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, ANDROGEN;

EID: 34548076585     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0163     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44.
3. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005;23:8253-61.
4. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
5. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004;164:217-27.
6. Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. J Urol 2006;176:S66-71.
7. Sharifi N, Farrar WL. Androgen receptor as a therapeutic target for androgen independent prostate cancer. Am J Ther 2006;13:166-70.
8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
9. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
10. Harrell JM, Murphy PJ, Morishima Y, et al. Evidence for glucocorticoid receptor transport on microtubules by dynein. J Biol Chem 2004;279:54647-54.
11. Martinez L, Webb P, Polikarpov I, Skaf MS. Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands. J Med Chem 2006;49:23-6.
12. Estebanez-Perpina E, Moore JM, Mar E, et al. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. J Biol Chem 2005;280:8060-8.
13. Hastie SB. Interactions of colchicine with tubulin. Pharmacol Ther 1991;51:377-401.
14. Berg U, Deinum J, Lincoln P, Kvassman J. Stereochemistry of colchicinoids. Enantiomeric stability and binding to tubulin of desacetamidocolchicine and desacetamidoisocolchicine. Bioorg Chem 1991;19:53-65.
15. Cogan PS, Koch TH. Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate. J Med Chem 2003;46:5258-70.
16. Bagnato JD, Eilers AL, Horton RA, Grissom CB. Synthesis and characterization of a cobalamin-colchicine conjugate as a novel tumor-targeted cytotoxin. J Org Chem 2004;69:8987-96.
17. Bohl CE, Miller DD, Chen J, Bell CE, Dalton JT. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem 2005;280:37747-54.
18. Ostrowski J, Kuhns JE, Lupisella JA, et al. Pharmacological and X-ray structural characterization of a novel selective androgen receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 2007;148:4-12.
19. Xiang Z, Soto CS, Honig B. Evaluating conformational free energies: the colony energy and its application to the problem of loop prediction. Proc Natl Acad Sci U S A 2002;99:7432-7.
20. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJ. GROMACS: fast, flexible, and free. J Comput Chem 2005;26:1701-18.
21. Schuettelkopf AW vAD. PRODRG - a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallographica 2004;D60:1355-63.
22. Izrailev S, Stepaniants S, Balsera M, Oono Y, Schulten K. Molecular dynamics study of unbinding of the avidin-biotin complex. Biophys J 1997;72:1568-81.
23. Hamel E. Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin. Cell Biochem Biophys 2003;38:1-22.
24. Verdier-Pinard P, Lai JY, Yoo HD, et al. Structure-activity analysis of the interaction of curacin A, the potent colchicine site antimitotic agent, with tubulin and effects of analogs on the growth of MCF-7 breast cancer cells. Mol Pharmacol 1998;53:62-76.
25. Mukherjee A, Kirkovsky L, Yao XT, Yates RC, Miller DD, Dalton JT. Enantioselective binding of Casodex to the androgen receptor. Xenobiotica 1996;26:117-22.
26. Christiansen RG, Bell MR, D'Ambra TE, et al. Antiandrogenic steroidal sulfonylpyrazoles. J Med Chem 1990;33:2094-100.
27. Brzozowski AM, Pike AC, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8.
28. Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α. Nature 1995;375:377-82.
29. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202.
30. Lin CM, Ho HH, Pettit GR, Hamel E. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry 1989;28:6984-91.
31. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci U S A 1994;91:3964-8.
32. Veldscholte J, Ris-Stalpers C, Kuiper GG, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-40.
33. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.